Ali Alavi1, Mohammad-Hosein Izadpanahi2, Leila Haghshenas3, Romina Faridizad1, Mohammad-Javad Eslami1, Keyvan Ghadimi1. 1. Department of Research, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran. 2. Department of Urology, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran. 3. Department of Molecular and Cellular Biology, International University of Spain Spain.
Abstract
BACKGROUND: The molecular mechanism of bladder cancer is yet not fully understood. Aim of this study was to compare the levels of BLCA-4 nuclear matrix protein in the urine of patients with bladder cancer and non-affected individuals. MATERIALS AND METHOD: The current cross sectional study was conducted on 45 patients with bladder cancer and 45 patients without bladder cancer who were referred to Alzahra Hospital of Isfahan, Iran in 2017. BCLA-4 Urinary Marker was measured in urine of the patients and individuals. Also correlation between the urine levels of BCLA-4 and other variables were evaluated. RESULTS: The urine levels of BLCA-4 in the patients with bladder cancer was significantly higher than non-bladder cancer group (P<0.001). There was no significant relationship between urine levels of BLCA-4 with tumor stage and size (P>0.05). CONCLUSION: The present study indicated that high urine levels of BLCA-4 was presented in patients with bladder cancer and this tumor marker has a high capability for early diagnosis of the disease, which can be used for screening and follow-up of bladder cancer. IJPPP
BACKGROUND: The molecular mechanism of bladder cancer is yet not fully understood. Aim of this study was to compare the levels of BLCA-4 nuclear matrix protein in the urine of patients with bladder cancer and non-affected individuals. MATERIALS AND METHOD: The current cross sectional study was conducted on 45 patients with bladder cancer and 45 patients without bladder cancer who were referred to Alzahra Hospital of Isfahan, Iran in 2017. BCLA-4 Urinary Marker was measured in urine of the patients and individuals. Also correlation between the urine levels of BCLA-4 and other variables were evaluated. RESULTS: The urine levels of BLCA-4 in the patients with bladder cancer was significantly higher than non-bladder cancer group (P<0.001). There was no significant relationship between urine levels of BLCA-4 with tumor stage and size (P>0.05). CONCLUSION: The present study indicated that high urine levels of BLCA-4 was presented in patients with bladder cancer and this tumor marker has a high capability for early diagnosis of the disease, which can be used for screening and follow-up of bladder cancer. IJPPP